TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05219084

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Normal; saline was injected subcutaneously
Study: NCT05281445

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tic suppression task
Description: Tic Suppression Task (TST, administered to Tourette syndrome participants only): At the beginning of the task, the child participant will be seated alone in front of a computer monitor with a countdown timer visible on the screen. For the first 10 minutes (baseline condition) they will be asked to tic freely and not to try to suppress their tics. For the second 10 minutes children will be asked to suppress their tics and will receive points for successful suppression. Participants will then be asked to sit alone in the room and tic freely for an additional 10-minutes.
Study: NCT05642754

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Overall uncertainty language
Description: Researchers are testing different forms of information about overall study uncertainty and margin of error around main result

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Overall uncertainty language
Description: Researchers are testing different forms of information about overall study uncertainty and margin of error around main result

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Overall uncertainty language
Description: Researchers are testing different forms of information about overall study uncertainty and margin of error around main result

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Overall uncertainty language
Description: Researchers are testing different forms of information about overall study uncertainty and margin of error around main result

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Overall uncertainty language
Description: Researchers are testing different forms of information about overall study uncertainty and margin of error around main result

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Overall uncertainty language
Description: Researchers are testing different forms of information about overall study uncertainty and margin of error around main result
Study: NCT05197985

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IECD Intervention
Description: The Nurturing Care curriculum contains: 1) responsive caregiving, 2) the important role everyone plays in raising a child, 3) maternal health and nutrition, 4) responsive feeding and good nutrition, 5) how children grow and develop, 6) hygiene, 7) language development, 8) the importance of play, 9) managing the stress of parenting, 10) protecting your child from harm. Modules will be delivered through group sessions for caregivers, individualized home visits and Social Behavior Change Communication. IECD will build families' capacity to grow and raise healthy food to consume themselves, and connect them to agricultural markets. Specifically, IECD will provide agriculture technical training to Village Model Farms and households, and will facilitate linkages to markets by identifying buyers and connecting them to the farmers. IECD will train and support volunteers to conduct disability screening, and train disability interventionists to provide appropriate therapies and support services.
Study: NCT05372289

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immuno-nutrition
Description: The experimental group of 68 older adults will be subjected to a preoperative immuno-nutrition for 30 days prior to surgery and up to 3 days after surgery. The oral feed provides energy, omega-3 fatty acids, arginine, nucleotides, and soluble fibre.
Study: NCT05538689

Intervention type: DRUG
Group type: OTHER
Intervention: Myfembree Oral Product
Description: The study drug Myfembree will be taken orally with water, once daily, at approximately the same time, with or without food. Each tablet of Myfembree contains Relugolix 40mg, estradiol 1mg, and norethindrone acetate 0.5 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myfembree Oral Product
Description: The study drug Myfembree will be taken orally with water, once daily, at approximately the same time, with or without food. Each tablet of Myfembree contains Relugolix 40mg, estradiol 1mg, and norethindrone acetate 0.5 mg.
Study: NCT06330649

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy Drink
Description: This is a commercially available energy drink

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water Control
Description: This is a commercially available bottled water
Study: NCT06254703

Intervention type: DIAGNOSTIC_TEST
Intervention: VexLUS (venous excess lung ultrasound)
Description: IVC, hepatic veins (HVs), portal veins (PVs) and intrarenal veins (IRVs), and lung ultrasound
Study: NCT06223451

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Repetitive Transcranial Magnetic Stimulation
Description: Repetitive Transcranial Magnetic Stimulation (rTMS) is a non-invasive brain stimulation method that can alter the excitability of the motor area by generating a magnetic field through a coil. Low-frequency stimulation (\<1 Hz) applied with rTMS has inhibitory effects. Repetitive transcranial magnetic stimulation has a neurorehabilitative role as it can modulate the excitability of targeted brain areas. Inhibitory repetitive transcranial magnetic stimulation will be applied to 11 patients with unilateral neglect due to ischemic stroke under the supervision of a doctor for a total of 10 sessions over 2 weeks with conventional rehabilitation.Each session will last for 20 minutes,total of 1200 pulses, 1 Hz repetitive transcranial manyetic stimulation over the unaffected left posterior parietal cortex.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive Transcranial Magnetic Stimulation
Description: Patients in the sham group will receive sham transcranial magnetic stimulation with sham coil for 20 minutes a day, 10 sessions in total, together with conventional rehabilitation.
Study: NCT05785533

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone App
Description: App that provides recovery guidance based on pain and functional outcomes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Paper based discharge instruction that provide information on pain management
Study: NCT05899608

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ivonescimab Injection
Description: Subject will receive ivonescimab and chemotherapy as an IV injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab Injection
Description: Subject will receive pembrolizumab and chemotherapy as an IV injection
Study: NCT06189703

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tRNS
Description: transcranial random noise stimulation applied to the right IFG and the left DLPFC

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tRNS
Description: transcranial random noise stimulation applied to the right IFG and the left DLPFC
Study: NCT06067048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib Oral Capsule
Description: 36 cycles (1 cycle is 28 days)
Study: NCT04698785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment by regorafenib and best supportive care
Description: Treatment for 13 cycles (12 months) maximum.~During each cycle :~* patients ≥ 16 years old and patients \<16 old with Body Surface Area (BSA) ≥ 1,70 m2 will take 3 tablets, once a day, corresponding to a total of 120 mg Regorafenib, during 21 days, followed by 7 days without treatment.~* patients \< 16 years old with a 1,30 m2 ≤ BSA ≥ 1,70 m2 will take 2 tablets, once a day, corresponding to a total of 80 mg Regorafenib, during 21 days, followed by 7 days without treatment
Study: NCT05961969

Intervention type: PROCEDURE
Intervention: Robotic surgery
Description: 1. Patients with rectal cancer.~2. Patients will undergo robotic Transabdominal Top-down Intersphincteric Resection with Double-stapling Coloanal Anastomosis
Study: NCT06465303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTP-026
Description: Intervention is for each subject administered as three 30-minutes infusions of either A: 25μg/kg RTP-026; or B: ≥ 26μg/kg and ≤75μg/kg RTP-026; or C: A maximum of 3 x treatment dose RTP-026 as given in B;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intervention is for each subject administered as three 30-minutes infusions of placebo
Study: NCT05569538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bomedemstat
Description: Bomedemstat will be self-administered orally once daily. In both cohorts, the dose of bomedemstat will be adjusted in each patient based on titration of the patient's platelet count to the target range. Ruxolitinib will be self-administered orally. Both medications will continue uninterrupted in 28-day cycles. Subjects will continue combination treatment through the Initial Treatment Period (first 6 cycles), which includes a Qualification Assessment. Those deriving clinical benefit in the opinion of the treating physician may continue receiving combination treatment in the Additional Treatment Period (6 cycles). Qualification Assessments will be performed at the end of each Additional Treatment Period, which is iterative, and may repeat for as long as clinical benefit is sustained, at the discretion of the treating physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bomedemstat
Description: Bomedemstat will be self-administered orally once daily. In both cohorts, the dose of bomedemstat will be adjusted in each patient based on titration of the patient's platelet count to the target range. Ruxolitinib will be self-administered orally. Both medications will continue uninterrupted in 28-day cycles. Subjects will continue combination treatment through the Initial Treatment Period (first 6 cycles), which includes a Qualification Assessment. Those deriving clinical benefit in the opinion of the treating physician may continue receiving combination treatment in the Additional Treatment Period (6 cycles). Qualification Assessments will be performed at the end of each Additional Treatment Period, which is iterative, and may repeat for as long as clinical benefit is sustained, at the discretion of the treating physician.
Study: NCT06464744

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Description: Intermittent Theta burst stimulation will be delivered on the on the primary motor cortex using a figure-of-eight coil, supported by neuronavigation. The stimulation intensity will be set to 90% of the motor threshold

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo stimulation using a placebo coil
Description: The placebo coil looks identical to the active coil but it only delivers skin tingling and no active brain stimulation.
Study: NCT05297279

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home delivery Omega-3 rich Food
Description: The active treatment arm will receive voucher (with a specified amount) weekly home delivery omega-3 rich food for the 12-weeks (3 months) intervention. Participants will be limited to purchasing foods rich in omega-3 only.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Motivational Coaching
Description: The active treatment arm will receive weekly personalize dietary couching by a dietary coach on omega-3 rich food for the 12-weeks intervention. Participant will also receive educational materials and guidance about what kind of food to order, how to cook, prepare (recipes) and store omega-3 rich foods.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Home delivery Food
Description: The control treatment arm will receive voucher (with a specified amount) weekly home delivery food (any kind of food) for the 12-weeks (3 months) intervention. Participant will not receive dietary coaching on food choices and will not be limited to purchasing foods rich in omega-3.
Study: NCT06599983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational program, Educational Storytelling, an Educational Program Against Child Abuse and Neglect.
Description: One day educational program, aiming at increase dental personnels attitude, knowledge and behaviour in regard to detect and report child abuse and neglect, and to treat patients with known and unknown history of child abuse and neglect.
Study: NCT05074888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prospekta
Description: Oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration.
Study: NCT06605794

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeFlow percutaneous atrial septal shunt
Description: The trial devices included a percutaneous atrial septal shunt and an atrial septal shunt delivery system. The specifications of the atrial septal shunt device were -φ5, φ7, φ9, φ11, and the specifications of the atrial septal shunt delivery system-FFISS-B were 9F and 10F.
Study: NCT06607367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (JAKAVI®)
Description: Initial starting dose will be 10mg BD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag (Revolade®)
Description: Initial starting dose will be 50mg daily
Study: NCT06606626

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Description: Partial (4h) or total (0h) sleep deprivation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Description: Partial (4h) or total (0h) sleep deprivation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Description: Partial (4h) or total (0h) sleep deprivation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep place
Description: 8h sleep at home or in the laboratory

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sleep place
Description: 8h sleep at home or in the laboratory
Study: NCT06606418

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture group
Description: The patients in this group received acupuncture treatment 3 times a week for 4 weeks. Acupuncture points selection: bilateral Fei Shu (BL13), Xin Shu (BL15), Ji Shu (BL17), Gan Shu (BL18), PI Shu (BL20), Shen Shu (BL23), Shangqiu (SP5), Yin Bai (SP5), foot Qioyin (GB44), Li Dui (ST45). Acupuncture operation method: The patient took the lateral position and used Huacheng acupuncture needle (body length 40mm, diameter 0.30mm) to skew 0.5\~0.8 inches at the back acupoint, 0.5\~0.8 inches at Shangqiu (SP5), 0.1 inches at Yin Bai (SP5), foot Qiaoyin (GB44) and Li Dui (ST45), and left the needle for 30 minutes to wait for qi.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture group
Description: The patients in this group received sham acupuncture treatment 3 times a week for 4 weeks. Sham acupuncture points are selected at sham points close to the acupoints of the acupuncture group: 3 inches beside Fei Shu (BL13), Xin Shu (BL15), Ji Shu (BL17), Gan Shu (BL18), PI Shu (BL20), Shen Shu (BL23), 1 inches below Shangqiu (SP5), 0.1 inches behind the middle edge of the great toe, second toe and fourth toenail of the foot. Acupuncture operation method: The patient took the lateral position and used Huacheng acupuncture needle (body length 40mm, diameter 0.30mm) to pierce the skin shallowly, and left the needle for 30 minutes.
Study: NCT06606639

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: acute caffeine intake (3 mg/kg)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: acute caffeine intake (3 mg/kg)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: acute caffeine intake (3 mg/kg)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Acute placebo intake (3 mg/kg of maltodextrin)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Acute placebo intake (3 mg/kg of maltodextrin)
Study: NCT06608836

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: an ice massage
Description: an ice massage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the cold spray
Description: the cold spray
Study: NCT06607861

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline group
Description: nebulization of 4 mL 0.9% saline twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine group
Description: nebulization of 1 µg/kg dexmedetomidine diluted in 4 mL 0.9% saline twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine group
Description: bilateral nebulization (60 mg) using a mucosal atomization device twice daily
Study: NCT06605001

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delay of Gratification
Description: Children will complete a delay of gratification task with 1 of 2 rewards

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delay of Gratification
Description: Children will complete a delay of gratification task with 1 of 2 rewards
Study: NCT05766631

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DynamiCare Health
Description: Participants earn incentives for:~1. CM for opioid and cocaine abstinence. Accomplished via oral fluid (saliva) test kits given to participants.~2. Patients who test negative on opioids and cocaine are also eligible for a bonus if they additionally test negative for non-targeted drugs (except methadone).~3. Patients will receive notices of their medication pickup appointments through the app itself, and monetary rewards will be delivered to the Next Step debit card when the participant's presence at the clinic is verified by clinic records.~4. The app provides 72 self-administered modules based on the principles of cognitive behavioral therapy that are designed to aid in relapse prevention; small incentive rewards ($1) are provided for completion of up to 3 modules per week for the first weeks of treatment.
Study: NCT04905446

Intervention type: OTHER
Group type: OTHER
Intervention: Deuterated nicotinamide (D4-NAM) IV infusion
Description: Nicotinamide adenine dinucleotide (NAD) is a vitally important substance that is found in all cells of the body. D4-NAM (in normal saline) will be infused via an indwelling catheter.The IV infusion will continue for 8 hrs.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Skeletal muscle biopsy
Description: Participants will have a muscle biopsy performed on the muscle in the thigh. We will collect a small sample of blood before the biopsy. This procedure is used to sample muscle cells from the right or left leg Vastus Lateralis (thigh) muscle.
Study: NCT05766631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone Treatment-As-Usual
Description: Participants will receive treatment-as-usual at the methadone clinic, including daily methadone dosing, individual and group addiction counseling, and OP or IOP behavioral health services, depending on the clinic and the needs of the patient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone Treatment-As-Usual
Description: Participants will receive treatment-as-usual at the methadone clinic, including daily methadone dosing, individual and group addiction counseling, and OP or IOP behavioral health services, depending on the clinic and the needs of the patient.
Study: NCT06761443

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: The experimental phase of this study had last 8 weeks and each patient will make 3 visits (week 0, week 4, week 8).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: The experimental phase of this study had last 8 weeks and each patient will make 3 visits (week 0, week 4, week 8).
Study: NCT06762067

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mirror therapy
Description: Participants will undergo physiotherapy exercises in a mirror alongside post-surgery care. The program includes palming exercises, eye exercises, pencil push-ups, Brock string exercises, thumb exercises, and proprioceptive neuromuscular facilitation exercises. The first exercise warms up extra ocular muscles, the second improves eye coordination, the third motivates the lazy eye, the fourth strengthens eye muscles, and the fifth involves a near-distance jump for oblique muscles.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional therapy
Description: The patients within the control group will receive traditional care post-strabismus operation as eye glasses and eye drops and regular exercise
Study: NCT05746650

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Description: Experimentally induced muscly injury via. neuromuscular electrical stimulation of the hamstring muscles

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Description: Experimentally induced muscly injury via. neuromuscular electrical stimulation of the hamstring muscles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth hormone (somatropin)
Description: Daily injection of growth hormone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Growth hormone (somatropin)
Description: Daily injection of growth hormone

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control (No electrical stimulation, nor growth hormone)
Description: No electrical stimulation, nor growth hormone
Study: NCT05401045

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Met exercises
Description: Exercise plan: Each session of the self-designed MET exercise program was divided into 8 components: stretching exercises, chest expansion exercises, kicking exercises, lateral movement exercises, body rotation exercises, whole-body exercises, jumping exercises, and a cool down. There are 4 sets and 8-repetitions per component, taking approximately 4 minutes to complete and consuming approximately 18 calories. Patients were instructed to exercise once in the morning and once in the evening. For patients with moderate fatigue and an RPFS score of 4 to 6 points, low-intensity exercise was recommended, i.e., patients could choose 1 to 4 metabolic equivalent exercises and repeat them twice; for patients with mild fatigue and an RPFS score of 1 to 3 points, moderate-intensity exercise was recommended, i.e., patients could choose to complete the entire set of metabolic equivalent exercises or 5 to 8 of the exercises and repeat them twice. The exercise frequency was 5 times per week.